Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2

Heat shock protein 90 (Hsp90) is a molecular chaperone that facilitates the correct folding and functionality of its client protein. Numerous Hsp90-client proteins are involved in cancer development. Thus, Hsp90 inhibitors have potential applications as anti-cancer drugs. We previously discovered that Hsp90α expression increased in breast cancer stem cells (BCSCs), which can initiate tumorigenesis and metastasis and resist treatment. In the present study, we further demonstrated that 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an inhibitor of Hsp90, could suppress the self-renewal of BCSCs by downregulating B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a polycomb family member with oncogenic activity in breast cancer. Through immunoprecipitation analysis, we found that BMI1 did not interact with Hsp90α and that the downregulation of BMI1 by 17-DMAG was mediated by the inhibition of c-Myc and enhancement of zeste homolog 2 (EZH2) expression. The transcriptional and BMI1 promoter-binding activities of c-Myc in BCSCs were inhibited by 17-DMAG treatment. The overexpression of EZH2 attenuated the inhibitory effect of 17-DMAG on BMI1 and c-Myc expression. Furthermore, Hsp90α could be co-immunoprecipitated with c-Myc and EZH2 and bind to the BMI1 promoter. Treatment with 17-DMAG decreased the nuclear expression of EZH2 and c-Myc but not that of Hsp90α. In conclusion, our data suggested that Hsp90α could positively regulate the self-renewal of BCSCs by facilitating the nuclear translocation of c-Myc and EZH2 to maintain BMI1 expression.


Introduction
Breast cancer is the most common cancer and the leading cause of cancer-related death among females worldwide [1]. Breast cancer can be classified into several subtypes on the basis of the expression profiles of hormone receptors and human epidermal growth factor receptor 2 (HER2): luminal A, luminal B, HER2+, and triple negative/basal-like breast cancer [2]. Triple-negative breast cancer cells (TNBC) are associated with the poor prognosis of patients and lack effective chemotherapy or targeting therapy agents [3,4]. Cancer stem/progenitor cells (CSCs) are a subpopulation of cancer cells with tumor initiation capacity and have an important role in cancer drug resistance, relapse, and metastasis [5,6]. Breast cancer stem/progenitor cells (BCSCs) are breast cancer cells that are characterized by the expression of specific markers, such as CD24-CD44 + [7], and the activity of intracellular aldehyde dehydrogenase (ALDH) [8]; these cells can be enriched through tumorsphere cultivation [9,10]. BCSCs are resistant to therapy, including radiation treatment [11,12] or chemotherapy [13,14]. Thus, targeting BCSCs may be a potential therapeutic strategy against breast cancer [5,10]. B lymphoma Mo-MLV insertion region 1 homolog (BMI1) is a member of the polycomb repression complex 1 (PRC1) family and regulates the self-renewal of normal and malignant stem cells by preventing senescence and apoptosis [15,16]. BMI1 is an independent prognostic factor of TNBC [17] and is essential for the self-renewal of BCSCs [18].
Heat shock protein 90 (Hsp90) is a molecular chaperone, a cellular protein that facilitates and maintains the correct folding of its client protein through the binding of ATP molecule [19]. Many Hsp90-client proteins, such as protein kinases, steroid hormone receptors, cycle regulators, and telomerase, are involved in oncogenesis [20]. Therefore, Hsp90 inhibitors have potential applications as anti-cancer drugs. Several Hsp90 inhibitors, which exert their inhibitory effect by competitively binding at the ATP binding site of the Hsp90 dimer, have been developed, and their therapeutic effect on cancer have been examined in clinical trials [21]. We previously discovered that Hsp90α expression is upregulated in ALDH + BCSCs [22]. Hsp90 inhibitors, including geldanamycin and its analog 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), could decrease the population of ALDH + BCSCs and the protein expression of Akt, a well-known client protein of Hsp90 that regulates cell survival and proliferation [22]. This finding suggested that Hsp90 inhibitors are potential and effective cancer chemotherapeutic drugs that target BCSCs. However, the mechanisms that underlie the anti-BCSC action of Hsp90 inhibitors should be further investigated.
In the present study, we further investigated the molecular mechanism that underlies the BCSC-targeting effect of 17-DMAG and discovered that BMI1 is downregulated in 17-DMAG-treated TNBC-derived mammosphere cells. We also demonstrated that the downregulation of BMI1 by 17-DMAG is mediated by the suppression of c-Myc transcriptional activity and the downregulation of the enhancer of zeste homolog 2 (EZH2), a PRC2 member. The overexpression of EZH2 prevents the downregulation of BMI1 or c-Myc in 17-DMAG-treated BCSCs. Finally, we discovered that Hsp90α complexes with EZH2 and c-Myc on the BMI1 promoter and functions as a shuttle that translocates EZH2 and c-Myc to the nucleus. Our data suggested that Hsp90α could positively regulate the self-renewal of BCSCs by facilitating the nuclear translocation of c-Myc and EZH2 to maintain BMI1 expression.

17-DMAG Inhibits the Self-Renewal Capability of BCSCs and Downregulates Their Expression of BMI1
We previously demonstrated that 17-DMAG could inhibit the expression of ALDH + in AS-B244 human breast cancer cells [22]. We enriched BCSCs through mammosphere cultivation to further examine the effect of 17-DMAG on the self-renewal of BCSCs [10]. As shown in Figure 1, 17-DMAG inhibited the mammosphere formation of AS-B244 and MDA-MB-231 TNBC cells in a dose-dependent manner. This finding suggested that 17-DMAG suppresses the proliferation of TNBC CSCs under non-adherent and serum-free cultivation conditions. Several studies have reported that BMI1 positively regulates the self-renewal capability and tumorigenicity of BCSCs [23][24][25][26]. We next examined the effect of 17-DMAG on BMI1 expression in AS-B244 or MDA-MB-231 mammosphere cells. Our Western blot data indicated that 17-DMAG inhibited BMI1 expression in AS-B244 and MDA-MB-231 mammosphere cells ( Figure 2A). Then, we used the immunoprecipitation method to determine if BMI1 is a client protein of Hsp90α. We found that the BMI1 protein is not co-precipitated by the anti-Hsp90α antibody ( Figure 2B). Through quantitative RT-PCR, we observed that BMI1 mRNA expression in AS-B244 and MDA-MB-231 mammosphere cells are downregulated by 17-DMAG treatment in a dose-dependent manner ( Figure 2C). These results indicated that 17-DMAG suppresses BMI1 expression through a transcriptional regulatory mechanism.
Int. J. Mol. Sci. 2017, 18,1986 3 of 13 inhibited the mammosphere formation of AS-B244 and MDA-MB-231 TNBC cells in a dose-dependent manner. This finding suggested that 17-DMAG suppresses the proliferation of TNBC CSCs under non-adherent and serum-free cultivation conditions. Several studies have reported that BMI1 positively regulates the self-renewal capability and tumorigenicity of BCSCs [23][24][25][26]. We next examined the effect of 17-DMAG on BMI1 expression in AS-B244 or MDA-MB-231 mammosphere cells. Our Western blot data indicated that 17-DMAG inhibited BMI1 expression in AS-B244 and MDA-MB-231 mammosphere cells ( Figure 2A). Then, we used the immunoprecipitation method to determine if BMI1 is a client protein of Hsp90α. We found that the BMI1 protein is not co-precipitated by the anti-Hsp90α antibody ( Figure 2B). Through quantitative RT-PCR, we observed that BMI1 mRNA expression in AS-B244 and MDA-MB-231 mammosphere cells are downregulated by 17-DMAG treatment in a dose-dependent manner ( Figure 2C). These results indicated that 17-DMAG suppresses BMI1 expression through a transcriptional regulatory mechanism.

Inhibitory Effect of 17-DMAG on BMI1 Expression Is Associated with Downregulated c-Myc Transcriptional Activity
c-Myc is a transcriptional factor that controls BMI1 expression [27]. Western blot results indicated that 17-DMAG inhibits c-Myc expression in a dose-dependent manner ( Figure 3A). The physical interaction between c-Myc and Hsp90 in Ras-overexpressed MCF7 breast cancer cells [28]. Subsequently, we examined the effect of 17-DMAG on the interaction between Hsp90α and c-Myc and found that 17-DMAG decreases the binding of Hsp90α and c-Myc in AS-B244 and MDA-MB-231 mammosphere cells ( Figure 3B). Using chromatin immunoprecipitation (ChIP) analysis, we found that 17-DMAG treatment inhibits the binding of c-Myc on the E-box region in the BMI1 promoter ( Figure 3C). Furthermore, the results of a luciferase-based reporter assay demonstrated that 17-DMAG downregulates the transcriptional activity of c-Myc in AS-B244 and MDA-MB-231 mammosphere cells ( Figure 3D). These results indicated that the loss of c-Myc protein due to 17-DMAG mediated inhibition of Hsp90α resulted in decreased transcription of c-Myc target genes, including BMI1 in BCSCs.

Inhibitory Effect of 17-DMAG on BMI1 Expression Is Associated with Downregulated c-Myc Transcriptional Activity
c-Myc is a transcriptional factor that controls BMI1 expression [27]. Western blot results indicated that 17-DMAG inhibits c-Myc expression in a dose-dependent manner ( Figure 3A). The physical interaction between c-Myc and Hsp90 in Ras-overexpressed MCF7 breast cancer cells [28]. Subsequently, we examined the effect of 17-DMAG on the interaction between Hsp90α and c-Myc and found that 17-DMAG decreases the binding of Hsp90α and c-Myc in AS-B244 and MDA-MB-231 mammosphere cells ( Figure 3B). Using chromatin immunoprecipitation (ChIP) analysis, we found that 17-DMAG treatment inhibits the binding of c-Myc on the E-box region in the BMI1 promoter ( Figure 3C). Furthermore, the results of a luciferase-based reporter assay demonstrated that 17-DMAG downregulates the transcriptional activity of c-Myc in AS-B244 and MDA-MB-231 mammosphere cells ( Figure 3D). These results indicated that the loss of c-Myc protein due to 17-DMAG mediated inhibition of Hsp90α resulted in decreased transcription of c-Myc target genes, including BMI1 in BCSCs.

17-DMAG-Idnuced Inhibition of BMI1 and c-Myc Expression in BCSCs Is Associated with Downregulated EZH2 Expression
EZH2, a member of PRC2, can transactivate c-Myc expression in glioblastoma cancer stem cells [29]. We tested whether EZH2 plays a role in the downregulation of BMI1 and c-Myc expression under 17-DMAG treatment. 17-DMAG inhibited EZH2 expression in MDA-MB-231 mammosphere cells at the protein ( Figure 4A) and mRNA ( Figure 4B) levels in a dose-dependent manner. A recent work has demonstrated that EZH2 directly interacted with Hsp90α within murine T cells, and the inhibition of Hsp90α by AYU922 induced rapid degradation of EZH2 [30]. We also observed that EZH2 interacts with Hsp90α in MDA-MB-231 mammosphere cells, and 17-DMAG can attenuate this interaction ( Figure 4C). Through RNA interference technique, we further found that BMI1 and c-Myc expression decreases in MDA-MB-231 mammosphere cells after EZH2 knockdown ( Figure  4D). We overexpressed EZH2 in MDA-MB-231 cells to further validate the involvement of EZH2 in the 17-DMAG-mediated downregulation of BMI1 and c-Myc. We performed Western blot analysis to observe BMI1 or c-Myc expression after 17-DMAG treatment. As shown in Figure 4E, EZH2 overexpression diminished the inhibitory effect of 17-DMAG on BMI1 and c-Myc expression.

17-DMAG-Idnuced Inhibition of BMI1 and c-Myc Expression in BCSCs Is Associated with Downregulated EZH2 Expression
EZH2, a member of PRC2, can transactivate c-Myc expression in glioblastoma cancer stem cells [29]. We tested whether EZH2 plays a role in the downregulation of BMI1 and c-Myc expression under 17-DMAG treatment. 17-DMAG inhibited EZH2 expression in MDA-MB-231 mammosphere cells at the protein ( Figure 4A) and mRNA ( Figure 4B) levels in a dose-dependent manner. A recent work has demonstrated that EZH2 directly interacted with Hsp90α within murine T cells, and the inhibition of Hsp90α by AYU922 induced rapid degradation of EZH2 [30]. We also observed that EZH2 interacts with Hsp90α in MDA-MB-231 mammosphere cells, and 17-DMAG can attenuate this interaction ( Figure 4C). Through RNA interference technique, we further found that BMI1 and c-Myc expression decreases in MDA-MB-231 mammosphere cells after EZH2 knockdown ( Figure 4D). We overexpressed EZH2 in MDA-MB-231 cells to further validate the involvement of EZH2 in the 17-DMAG-mediated downregulation of BMI1 and c-Myc. We performed Western blot analysis to observe BMI1 or c-Myc expression after 17-DMAG treatment. As shown in Figure 4E

17-DMAG Interferes with the Hsp90α-Facilitated Nuclear Translocation of c-Myc and EZH2
We investigated the possibility of the formation of the Hsp90α/c-Myc complex within the BMI1 promoter. Using anti-Hsp90α or anti-EZH2 antibody to perform ChIP analysis, we amplified the c-Myc binding region within the BMI1 promoter through qRT-PCR. The results indicated that Hsp90α or EZH2 complexes with c-Myc to bind with the BMI1 promoter ( Figure 5A, DMSO group of tRFP overexpressed cells). Treatment with 17-DMAG decreases the binding of EZH2/c-Myc complex on the BMI1 promoter, whereas the overexpression of EZH2 can overcome the inhibitory effect of 17-DMAG ( Figure 5A). Given that Hsp90α participates in the nuclear-cytoplasmic shuttling of the mineralocorticoid receptor [31], we then investigated the effect of 17-DMAG on the Hsp90α-mediated nuclear-cytoplasmic shuttling of EZH2 or c-Myc. We isolated nuclear and cytosolic proteins and used equal amounts of nuclear and cytoplasmic proteins for immunoprecipitation ( Figure 5B). When anti-Hsp90α antibody was used to perform immunoprecipitation, the Hsp90α/c-Myc/EZH2 complex localized in the nucleus ( Figure 5C, DMSO group). By calculating the nuclear/cytoplasmic ratio of Hsp90α-shuttled EZH2-or c-Myc, we found that only EZH2 content decreased from 82.0% to 68.2% in response to 17-DMAG treatment ( Figure 5C. However, 17-DMAG treatment decreased the nuclear content of Hsp90α-shuttled EZH2 and c-Myc ( Figure 5C, 17-DMAG group), but not the nuclear entrance of Hsp90α ( Figure 5C). These results suggested that the

17-DMAG Interferes with the Hsp90α-Facilitated Nuclear Translocation of c-Myc and EZH2
We investigated the possibility of the formation of the Hsp90α/c-Myc complex within the BMI1 promoter. Using anti-Hsp90α or anti-EZH2 antibody to perform ChIP analysis, we amplified the c-Myc binding region within the BMI1 promoter through qRT-PCR. The results indicated that Hsp90α or EZH2 complexes with c-Myc to bind with the BMI1 promoter ( Figure 5A, DMSO group of tRFP overexpressed cells). Treatment with 17-DMAG decreases the binding of EZH2/c-Myc complex on the BMI1 promoter, whereas the overexpression of EZH2 can overcome the inhibitory effect of 17-DMAG ( Figure 5A). Given that Hsp90α participates in the nuclear-cytoplasmic shuttling of the mineralocorticoid receptor [31], we then investigated the effect of 17-DMAG on the Hsp90α-mediated nuclear-cytoplasmic shuttling of EZH2 or c-Myc. We isolated nuclear and cytosolic proteins and used equal amounts of nuclear and cytoplasmic proteins for immunoprecipitation ( Figure 5B). When anti-Hsp90α antibody was used to perform immunoprecipitation, the Hsp90α/c-Myc/EZH2 complex localized in the nucleus ( Figure 5C, DMSO group). By calculating the nuclear/cytoplasmic ratio of Hsp90α-shuttled EZH2-or c-Myc, we found that only EZH2 content decreased from 82.0% to 68.2% in response to 17-DMAG treatment ( Figure 5C. However, 17-DMAG treatment decreased the nuclear content of Hsp90α-shuttled EZH2 and c-Myc ( Figure 5C, 17-DMAG group), but not the nuclear entrance of Hsp90α ( Figure 5C). These results suggested that the inhibition of Hsp90α activity by 17-DMAG leads to the decrease of the nuclear translocation of EZH2 and c-Myc and causes the downregulation of BMI1 in BCSCs.

Discussion
BMI1, a PRC1 member, prevents cellular senescence through its transcriptional repressor function, thus maintaining the self-renewal of normal or malignant stem cells [32]. Targeting BMI1 expression by PTC596, a novel small molecule inhibitor of BMI1, exhibits effective anti-CSC activity in animal models without interfering with normal stem cells [33]. In the present study we discovered, for the first time, that 17-DMAG, an Hsp90 inhibitor, downregulates BMI1 in TNBC CSCs. 17-DMAG displays anti-tumor activity in MDA-MB-231 xenograft SCID mice model [34] and is retained longer in tumors than in normal tissues [35]. A phase I clinical trial has been conducted to determine the toxicity of 17-DMAG in patients with advanced malignancies, including stage IV and recurrent breast cancers; the results of the trial revealed that the patients tolerated twice-weekly intravenous infusions of 17-DMAG well [36]. Our results, and those of previous studies, collectively suggested that 17-DMAG is a potential chemotherapeutic drug for breast cancer.

Discussion
BMI1, a PRC1 member, prevents cellular senescence through its transcriptional repressor function, thus maintaining the self-renewal of normal or malignant stem cells [32]. Targeting BMI1 expression by PTC596, a novel small molecule inhibitor of BMI1, exhibits effective anti-CSC activity in animal models without interfering with normal stem cells [33]. In the present study we discovered, for the first time, that 17-DMAG, an Hsp90 inhibitor, downregulates BMI1 in TNBC CSCs. 17-DMAG displays anti-tumor activity in MDA-MB-231 xenograft SCID mice model [34] and is retained longer in tumors than in normal tissues [35]. A phase I clinical trial has been conducted to determine the toxicity of 17-DMAG in patients with advanced malignancies, including stage IV and recurrent breast cancers; the results of the trial revealed that the patients tolerated twice-weekly intravenous infusions of 17-DMAG well [36]. Our results, and those of previous studies, collectively suggested that 17-DMAG is a potential chemotherapeutic drug for breast cancer. BMI1, EZH2, and c-Myc have a complicated relationship. The expression of c-Myc-accelerated BMI1/estrogen receptor in human mammary epithelial cells induces tumor formation [37]. In breast cancer cells, BMI1 can repress the dickkopf WNT signaling pathway inhibitor 1 and induce c-Myc expression to further activate BMI1 expression [38]. c-Myc and EZH2 interact in glioblastoma CSCs, and c-Myc overexpression rescues the inhibitory effect of 3-deazaneplanocin A, an EZH2 inhibitor, on targeted glioblastoma CSCs [29]. Moreover, silencing c-Myc in embryonic stem cells (ESCs) suppresses the expression of PRC2 proteins and upregulates the expression of genes involved in primitive endoderm differentiation [39]. This finding suggested that the undifferentiated status of ESCs is maintained by the interaction between c-Myc and PRC2. In the present study we discovered, for the first time, that BMI1, c-Myc, and EZH2 are linked by Hsp90α. 17-DMAG treatment decreases c-Myc and EZH2 content in the nuclei of TNBC CSCs ( Figure 5C) and the binding of EZH2 on the E-box region of the BMI1 promoter ( Figure 5B) without interfering with the nuclear translocation of Hsp90α ( Figure 5C). These results suggested that Hsp90α could function as a shuttle that facilitates the nuclear transport of EZH2 and c-Myc to mediate BMI1 transcription in TNBC CSCs and lead to the self-renewal of these cells ( Figure 6). The central region of Hsp90α involved in shuttling EZH2 and c-Myc from the cytoplasm to the nucleus requires further study.
Int. J. Mol. Sci. 2017, 18,1986 8 of 13 BMI1, EZH2, and c-Myc have a complicated relationship. The expression of c-Myc-accelerated BMI1/estrogen receptor in human mammary epithelial cells induces tumor formation [37]. In breast cancer cells, BMI1 can repress the dickkopf WNT signaling pathway inhibitor 1 and induce c-Myc expression to further activate BMI1 expression [38]. c-Myc and EZH2 interact in glioblastoma CSCs, and c-Myc overexpression rescues the inhibitory effect of 3-deazaneplanocin A, an EZH2 inhibitor, on targeted glioblastoma CSCs [29]. Moreover, silencing c-Myc in embryonic stem cells (ESCs) suppresses the expression of PRC2 proteins and upregulates the expression of genes involved in primitive endoderm differentiation [39]. This finding suggested that the undifferentiated status of ESCs is maintained by the interaction between c-Myc and PRC2. In the present study we discovered, for the first time, that BMI1, c-Myc, and EZH2 are linked by Hsp90α. 17-DMAG treatment decreases c-Myc and EZH2 content in the nuclei of TNBC CSCs ( Figure 5C) and the binding of EZH2 on the E-box region of the BMI1 promoter ( Figure 5B) without interfering with the nuclear translocation of Hsp90α ( Figure 5C). These results suggested that Hsp90α could function as a shuttle that facilitates the nuclear transport of EZH2 and c-Myc to mediate BMI1 transcription in TNBC CSCs and lead to the self-renewal of these cells ( Figure 6). The central region of Hsp90α involved in shuttling EZH2 and c-Myc from the cytoplasm to the nucleus requires further study. Figure 6. The working hypothesis of Hsp90-mediated BMI1 expression in BCSCs through the EZH2 and c-Myc pathways. One of the functions of Hsp90α is to facilitate the nuclear translocation of EZH2 and c-Myc and binding to the E-Box region of the BMI1 promoter to drive BMI1 expression and regulates the self-renewal of BCSCs. The Hsp90α mediated BMI1 expression could be inhibited by 17-DMAG, a specific Hsp90 inhibitor, which binds to ATP-binding pocket of the Hsp90 dimer.

Immunoprecipitation and ChIP Analysis
Five hundred micrograms (500 µg) of total cellular, cytoplasmic, or nuclear proteins were extracted and used for immunoprecipitation by adding 1 µg of anti-Hsp90α antibody in NP-40 cell lysis buffer and incubating at 4 • C for overnight. Ten microliters (10 µL) of Protein G Mag Sepharose Xtra beads (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) were then added and incubated at room temperature for 2 h. After washing steps, precipitated proteins were then eluted by adding 1× sample loading dye and incubated at 95 • C for 10 min. Immunoprecipitated proteins were analyzed by Western blot analysis. For ChIP analysis, cells were fixed with 1% formaldehyde at room temperature for 10 min. After quenching the formaldehyde with 125 mM glycine, the cells were lysed with mammalian cell lysis buffer (Pierce, Thermo Fisher Scientific, Inc., Waltham, MA USA) and chromatins were sonicated into fragments with lengths of 500 base-pairs. The ChIP analysis was then performed according to the previous report [40]. The c-Myc binding region of BMI1 promoter was detected by SYBR Green based quantitative PCR using the following primer set: forward primer: 5 -CACGGGCCTGACTACACCGACACT-3 ; reverse primer: 5 -CACCGCTGAAGGCAGAGTGGAAAC-3 .

Determination of the Transcriptional Activity of c-Myc
Cells were seeded as 2 × 10 5 cells/well in a six-well plate and co-transfected with pMyc-Luc reporter (Signosis, Inc. Santa Clara CA, USA) and pRL-TK Renilla reporter (Promega Corporation, Madison, WI, USA) plasmids at a ratio of 50:1 with TurboFect transfection reagent (Thermo Fisher Scientific Inc.) for 24 h. After treatment of 17-DMAG for a further 48 h, cells were lysed with 200 µL passive lysis buffer (Promega) and determined the luciferase activity with Beetle-Juice (for firefly luciferase (FLuc)) and Gaussia-Juice (for Renilla luciferase (RLuc)) substrates (PJK GmbH, Kleinblittersdorf, Germany), and luminescence was counted on a luminescence reader (Promega). The c-Myc transcriptional activity was determined according to the FLuc count after normalization to RLuc, which represented the transfection efficiency of each sample.

RNA Interference
The EZH2-specific shRNA carrying lentiviral vectors (TRCN0000040073, TRCN0000040076, and TRCN0000010475, obtained from the National RNAi Core Facility at the Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan) were used to produce lentivirus particles as described in our previous report [40]. The knockdown of the EZH2 gene was performed with lentiviral transduction of mixed EZH2-specific shRNA virus particles as a ratio of 1:1:1 in the presence of 8 µg/mL polybrene and the successfully transduced cells were selected by 2 µg/mL puromycin (TOKU-E Co., Bellingham, WA, USA). A luciferase-specific shRNA (TRCN0000231722) was used as the negative control.

Overexpression of EZH2 with Lentivirus Transduction
EZH2 gene was amplified from cDNA of MDA-MB-231 cells with following primers: 5 -ATCG CTAGCATGGGCCAGACTGGGAAgAAATC-3 and 5 -CGCATGCATTCAAGGGATTTCCATTTCTC TTTCG-3 . After digestion with NheI and NsiI, the amplified EZH2 fragment was cloned into pLAS5w.Pbsd-L-tRFP-C lentiviral vector (purchased form RNAi Core Facility in Academia Sinica, Taipei, Taiwan). The lentivirus particles were produced as described previously [24]. The transduction of lentivirus was performed by the addition of 8 µg/mL polybrene (Sigma) and blasticidin S (BSD, purchased from TOKU-E Co. Bellingham, WA, USA) was used for the selection of successfully-transduced cells at a concentration of 20 µg/mL.

Isolation of Cytosolic and Nuclear Proteins
The cytoplasmic and nuclear proteins of mammosphere cells were differentially isolated by FOCUS TM Cytoplasmic and Nuclear Protein Fractionation Kit (G-Biosciences, St. Louis, MO, USA) according to the manufacture's recommendation. Briefly, 1 × 10 6 cells were harvested and washed with phosphate-balanced solution (PBS) and incubated in 20 µL ice cold SubCell buffer-I for 10 min. The cells were then lysed up and down ten times with a 20 G syringe needle. The cytoplasmic proteins were collected by adding 40 µL of 3× SubCell buffer-II and performing centrifugation at 700× g for 10 min. The nuclear pellet was further washed with 500 µL 1× SubCell buffer-II and SubCell buffer-III to remove the remaining cytoplasmic proteins. The nuclear proteins were finally obtained by lysing the nuclear pellet with 20 µL of SubCell buffer IV.

Conclusions
We discovered that 17-DMAG, an Hsp90 inhibitor, could inhibit the self-renewal of TNBC CSCs. This effect is associated with the suppression of BMI1 caused by the decreased amounts of Hsp90α-shuttled EZH2 and c-Myc to the nucleus. Our data suggested that 17-DMAG has potential applications as an effective anti-CSC chemotherapeutic drug.